Semax: resolve the entity first
Semax is the ACTH(4–7)-derived heptapeptide MEHFPGP. Most translational discussion is route-specific. Intranasal findings cannot be borrowed to support an injectable product or an unidentified formulation.
Semax · Clinical molecule review
Semax: mechanism, evidence and clinical review.
Clinic Terrain reviews Semax molecule by molecule, identity, mechanism, human evidence, individual fit and the verification required before any protocol could be proposed.
For people asking whether Semax is relevant to a defined objective, not looking for an unverified vial or an automatic protocol.Request a Semax review →
Identity · the ACTH(4–7)-derived heptapeptide MEHFPGP
Evidence · molecule-specific monograph
Decision · physician reviewed
Product · verified before any proposal
Scientific dossier
Read the complete biochemistry-first monograph.
The scientific page treats identity, target architecture, signalling, pharmacology, physiology, counterevidence and falsification independently from the service offer.
What Semax can plausibly act on
The relevant causal architecture is neurotrophic and melanocortin-adjacent signalling studied principally by the intranasal route. Neurotrophic or transcriptional signals are mechanistically meaningful but do not establish durable cognitive benefit across diagnoses, routes or doses.
The decision inputs that change the answer
Attention, cognitive fatigue, neurological recovery and performance goals require different baselines. Sleep, anxiety, medication, substance exposure and neurological red flags are resolved first.
What must be resolved before any Semax protocol
Clinical relevance is only the first gate. A proposed route would also require a lawful pathway, current availability, exact formulation and presentation, responsible source, current lot, matching analytical documentation, receipt and storage controls. Clinic Terrain does not infer those facts from the molecule name or from a monograph.
How response to Semax is adjudicated
The plan predefines a cognitive or functional measure, time window, sleep and anxiety context, tolerability and a stopping rule instead of accepting novelty or stimulation as success. Continue, refine and stop decisions remain attached to the physician-reviewed record.
Direct answers
What to resolve before requesting this molecule.
Can Clinic Terrain assess a Semax request?
Yes. The clinical team can review the molecule, evidence and individual question. Assessment does not promise that a product is indicated, lawfully available, verified or supplied. Semax access is route- and objective-specific. Intranasal evidence cannot be used to justify an injectable product, while cognitive or neurological red flags may require a different clinical route first.
Does Clinic Terrain publish a price for Semax?
No current product price is published for Semax. A commercial quote would be inappropriate before the lawful route, exact presentation, current availability and matching product documentation are resolved.
What evidence cannot be inferred for Semax?
Neurotrophic or transcriptional signals are mechanistically meaningful but do not establish durable cognitive benefit across diagnoses, routes or doses.
What would Clinic Terrain monitor with Semax?
The plan predefines a cognitive or functional measure, time window, sleep and anxiety context, tolerability and a stopping rule instead of accepting novelty or stimulation as success.
Evidence position
The evidence is applied to the specific clinical question. It supports an individual assessment; it does not replace diagnosis or guarantee an outcome.
Sources used for this page
Primary sourceLebedeva et al. Bull Exp Biol Med. 2018;165:653–656. ↗Semax is the defined heptapeptide Met-Glu-His-Phe-Pro-Gly-Pro, derived from an ACTH(4–7) motif with a Pro-Gly-Pro extension.Primary sourceDolotov et al. Semax binding and BDNF increase in rat basal forebrain. J Neurochem. 2006. ↗Preclinical studies report BDNF/TrkB and neuroplasticity-related changes.Primary sourceGusev et al. Zh Nevrol Psikhiatr. 2018;118:61–68. ↗A small resting-state fMRI study included 24 healthy participants and reported network-level change.Regulatory guidanceWHO: good storage and distribution practices for medical products ↗This guidance defines supply-chain controls only. It does not prove the identity, purity, sterility or suitability of a specific product or lot.Primary sourceDmitrieva et al. Semax regulates immune-response genes during ischemic brain injury in rats. BMC Genomics. 2017. ↗Imaging change does not establish cognitive benefit, and historical non-equivalent controls do not support a universal neuroprotection claim.Regulatory guidanceICH: harmonised pharmaceutical quality guidelines ↗This framework explains what a quality system must establish. It is not analytical evidence for a Clinic Terrain product or lot.Your first message · Where you are + what you need help with